Hsin-Ho Liu
Overview
Explore the profile of Hsin-Ho Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai T, Chu T, Lin T, Hsieh T, Chen C, Liu H, et al.
PLoS One
. 2023 Mar;
18(3):e0283040.
PMID: 36928100
This study investigates age-specific prostate-specific antigen (PSA) distributions in Taiwanese men and recommends reference ranges for this population after comparison with other studies. From January 1999 to December 2016, a...
2.
Wu S, Jhang J, Liu H, Chen J, Li J, Chiu B, et al.
J Clin Med
. 2022 Dec;
11(24).
PMID: 36555924
Bladder dysfunction is a common complication after chronic spinal cord injury (SCI). Patients may experience renal function loss, urinary tract infection (UTI), urolithiasis, bladder cancer, and even life-threatening events such...
3.
Liu H, Kuo H
Urology
. 2019 Jun;
131:83-88.
PMID: 31150690
Objective: To investigate the long-term durability of retropubic suburethral sling procedure for female stress urinary incontinence (SUI) and to identify urodynamic factors that might predict long-term successful outcomes. Materials And...
4.
Lin H, Liu H, Lin C, Kao M, Chen Y, Chiang-Ni C, et al.
Front Cell Infect Microbiol
. 2017 Jun;
7:223.
PMID: 28642840
Cytolethal distending toxin (CDT) produced by contains three subunits: CdtA, CdtB, and CdtC. Among these three toxin subunits, CdtB is the toxic moiety of CDT with DNase I activity, resulting...
5.
Yang Y, Liu H, Lin T, Chuang H, Hsieh T
PLoS One
. 2017 Apr;
12(4):e0175335.
PMID: 28384267
Background: The effects of oxybutynin, solifenacin and tolterodine on dementia risk in patients with diabetes mellitus (DM) remain unknown. We investigated the effects of oxybutynin, solifenacin and tolterodine on dementia...
6.
Liu H, Tsai T, Lee S, Kuo Y, Hsieh T
PLoS One
. 2016 Aug;
11(8):e0160689.
PMID: 27513673
Background: The aim of this study was to determine the subsequent risk of acute urine retention and prostate surgery in patients receiving alpha-1 blockers treatment and having a maximum urinary...
7.
Yang Y, Lee S, Chen C, Liu H, Tsai T, Lin T, et al.
Cancer Med
. 2015 Nov;
5(1):3-8.
PMID: 26588887
Patients with prostate cancer have an increased risk of stroke, but their absolute rate of stroke depends on age and comorbid conditions. The Charlson Comorbidity Index Score (CCIS) is a...
8.
Lai C, Su J, Lin Y, Chang C, Feng C, Lin H, et al.
Future Microbiol
. 2015 Apr;
10(4):489-501.
PMID: 25865189
Aim: The aim of this study was to investigate whether cholesterol plays a pivotal role in cytolethal distending toxin (CDT) mediated pathogenic effects in hosts. Materials & Methods: The molecular...
9.
Hsieh T, Yang Y, Lee S, Lin T, Liu H, Tsai T, et al.
PLoS One
. 2015 Mar;
10(3):e0119694.
PMID: 25803433
Background: This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan....
10.
Liu H, Tsai Y, Lai C, Tang C, Lai C, Wu H, et al.
Biomedicine (Taipei)
. 2014 Dec;
4:2.
PMID: 25520915
With advances in molecular biologic and genomic technology, detailed molecular mechanisms for development of castration-resistant prostate cancer (CRPC) have surfaced. Metastatic prostate cancer (PCa) no longer represents an end stage,...